Medullary thyroid cancer: The role of radiotherapy in local control

被引:43
作者
Fife, KM [1 ]
Bower, M [1 ]
Harmer, CL [1 ]
机构
[1] ROYAL MARSDEN HOSP, THYROID UNIT, LONDON SW3 6JJ, ENGLAND
来源
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY | 1996年 / 22卷 / 06期
关键词
medullary thyroid cancer; radiotherapy;
D O I
10.1016/S0748-7983(96)92294-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Fifty-one patients were treated with radiotherapy for loco-regional medullary thyroid cancer between 1960-1992, The actuarial overall survival at 5, 10 and 20 years was 69%, 52% and 30%, respectively Patients were classified according to clinical stage (node-positive or -negative), post-operative histological residual disease status (none, microscopic or macroscopic) and dose of radiotherapy received, By univariate analysis, loco-regional recurrence-free survival was significantly longer for node-negative patients (P=0,03), Patients who received at least 60 Gy over 6 weeks showed a trend towards improved local control (P=0.23), The only significant variable by multivariate analysis for local recurrence-free survival was post-operative residual disease status (P=0.0005), The local control rate at 5 years was 100% for patients with no residual disease, 65% for those with microscopic tumour, and 24% for those with macroscopic residual disease, We conclude that there is a valuable role for radiotherapy in the management of patients with residual microscopic or macroscopic disease following surgery, as well as in those with inoperable disease.
引用
收藏
页码:588 / 591
页数:4
相关论文
共 50 条
  • [31] Metastatic Medullary Thyroid Cancer (MTC): Is There a Role for Peptide Receptor Radionuclide Therapy (PRRT)?
    Hayes, A. R.
    Crawford, A.
    Al Riyami, K.
    Tang, C.
    Wild, D.
    Khoo, B.
    Caplin, M.
    Nicolas, G.
    Grossman, A. B.
    NEUROENDOCRINOLOGY, 2019, 108 : 273 - 273
  • [32] How I treat medullary thyroid cancer
    Kiesewetter, B.
    Riss, P.
    Scheuba, C.
    Raderer, M.
    ESMO OPEN, 2021, 6 (03)
  • [33] Vandetanib and the management of advanced medullary thyroid cancer
    Campbell, Michael J.
    Seib, Carolyn D.
    Gosnell, Jessica
    CURRENT OPINION IN ONCOLOGY, 2013, 25 (01) : 39 - 43
  • [34] Surgical management of sporadic medullary thyroid cancer
    Noullet, S.
    Tresallet, C.
    Godiris-Petit, G.
    Hoang, C.
    Leenhardt, L.
    Menegaux, F.
    JOURNAL OF VISCERAL SURGERY, 2011, 148 (04) : E244 - E249
  • [35] Medullary thyroid cancer presenting with airway obstruction
    Shah, P.
    Reddy, C.
    Lawrence, R.
    Sudarshan, P.
    Wilne, S.
    Daniel, M.
    INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY EXTRA, 2016, 14 : 1 - 3
  • [36] Vandetanib for the Treatment of Metastatic Medullary Thyroid Cancer
    Degrauwe, Nils
    Sosa, Julie Ann
    Roman, Sanziana
    Deshpande, Hari A.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2012, 6 : 243 - 252
  • [37] The value of genetic screening in medullary thyroid cancer
    Pappa, Theodora
    Alevizaki, Maria
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2014, 9 (01) : 19 - 29
  • [38] Medical Management of Metastatic Medullary Thyroid Cancer
    Maxwell, Jessica E.
    Sherman, Scott K.
    O'Dorisio, Thomas M.
    Howe, James R.
    CANCER, 2014, 120 (21) : 3287 - 3301
  • [39] Targeted Therapy for Medullary Thyroid Cancer: A Review
    Priya, S. R.
    Dravid, Chandra Shekhar
    Digumarti, Raghunadharao
    Dandekar, Mitali
    FRONTIERS IN ONCOLOGY, 2017, 7
  • [40] Initial surgical management of medullary thyroid cancer
    Coan, Kathryn E.
    Wang, Tracy S.
    INTERNATIONAL JOURNAL OF ENDOCRINE ONCOLOGY, 2016, 3 (03) : 259 - 266